Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances
Open Access
- 21 March 2024
- journal article
- research article
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (6) , 3707-3722
Abstract
The landscape of current tumor treatment has been revolutionized by the advent of immunotherapy based on PD-1/PD-L1 inhibitors. Leveraging its capacity to mobilize systemic antitumor immunity, which is primarily mediated by T cells, there is growing exploration and expansion of its potential value in various stages of clinical tumor treatment. Neoadjuvant immunotherapy induces a robust immune response against tumors prior to surgery, effectively facilitating tumor volume reduction, early eradication or suppression of tumor cell activity, and control of potential metastatic spread, to improve curative surgical resection rates, and prevent tumor recurrence. This review delineates the theoretical basis of neoadjuvant immunotherapy from preclinical research evidence, discusses specific challenges in clinical application, and provides a comprehensive overview of clinical research progress in neoadjuvant immunotherapy for gastrointestinal tumors. These findings suggest that neoadjuvant immunotherapy has the potential to ameliorate immunosuppressive states and enhance cytotoxic T cell function while preserving lymphatic drainage in the preoperative period. However, further investigations are needed on specific treatment regimens, suitable patient populations, and measurable endpoints. Despite numerous studies demonstrating the promising efficacy and manageable adverse events of neoadjuvant immunotherapy in gastrointestinal tumors, the availability of high-quality randomized controlled trials is limited, which highlights the necessity for further research.Keywords
This publication has 85 references indexed in Scilit:
- Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled StudyJournal of Clinical Oncology, 2019
- Clonal replacement of tumor-specific T cells following PD-1 blockadeNature Medicine, 2019
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignanciesJournal of Hematology & Oncology, 2019
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and MemoryCell, 2019
- Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and RadiotherapyInternational Journal of Molecular Sciences, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver MetastasisCell Metabolism, 2018
- Effects of surgery and anesthetic choice on immunosuppression and cancer recurrenceJournal of Translational Medicine, 2018
- Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic DiseaseCancer Discovery, 2016
- Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathwayCancer Immunology, Immunotherapy, 2015